Last reviewed · How we verify
NCT04615520
Evaluation of Surgical Risk Prediction Tools.
trial in Emergency Laparotomy in 660 participants. Completed in 1 August 2021.
1 August 2021
Quick facts
| Lead sponsor | University Hospital of Crete |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 660 |
| Start date | 1 May 2020 |
| Primary completion | 1 August 2021 |
| Estimated completion | 1 August 2021 |
| Sites | 1 location across Greece |
Conditions studied
- Emergency Laparotomy — all drugs for Emergency Laparotomy →
Sponsor
University Hospital of Crete
Who can join
18 and older, any sex, with Emergency Laparotomy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Introduction: In modern surgery, the prediction of perioperative death gains significant importance due to the availability of treatment options, means of improving the surgical outcome and for proper patient information. However, patient heterogeneity and the existence of multiple risk prediction tools complicate the prediction of perioperative mortality. Thus, prognostic tools are developed based on the analysis of preoperative variables. Most commonly used models are POSSUM, ACS-NSQIP, NELA and POTTER. The models have been assessed in West-European and North-American populations, each with different prognostic value. Aim: Comparative analysis of predictive accuracy of the aforementioned risk prediction tools in Greek population. Materials and Methods: The study is multicenter, non-interventional, prospective and observational and includes patients undergoing emergency laparotomies of general surgery. In cases of multiple operations in one hospitalization, the first operation is included. The clinical-laboratory variables, derived from POSSUM, NELA, ACS-NSQIP and POTTER models are recorded anonymously in a secure online database, REDCap (Research Electronic Data Capture).The minimum estimated number of included patients in order to accomplish statistically significant results is 600. Each of the centers submitted in the study, is expected to include approximately 60 patients in a period of 6-12 months. For the statistical analysis of data, Brier Score will be used and ROC with statistical significance lower than 0.05. Conclusions: Upon completion of this study, the most accurate perioperative risk prediction tool in the Greek population is expected to be proposed.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The Hellenic Emergency Laparotomy Study (HELAS): A Prospective Multicentre Study on the Outcomes of Emergency Laparotomy in Greece.
Lasithiotakis K, Kritsotakis EI, Kokkinakis S, Petra G, et al · · 2023 · cited 18× · PMID 36109368 · DOI 10.1007/s00268-022-06723-6
Verify or expand the search:
- PubMed search for NCT04615520
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University Hospital of Crete trials
Trials by the same sponsor.
- NCT06405906 — A Randomized Controlled Trial Comparing Fat-free Versus Balanced (WHO) Diet in Gallstone Disease · NA · recruiting
- NCT05393752 — Malnutrition Assessment Tools in Surgery · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04615520 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital of Crete
- Last refreshed: 28 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04615520.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing